# Fred Hutch account plan

> Fred Hutch is a Seattle not-for-profit, NCI-designated comprehensive cancer center with $2,511,452 thousand of FY2025 revenues and 6,200+ staff.

## At a glance

Fred Hutchinson Cancer Center (Fred Hutch) is a Washington not-for-profit, 501(c)(3) corporation and an NCI-designated comprehensive cancer research center in Seattle, formed in April 2022 when Fred Hutchinson Cancer Research Center combined with the Seattle Cancer Care Alliance. It runs a clinically integrated adult oncology program with UW Medicine, combining patient care (a 20-bed licensed hospital, ambulatory cancer care, a proton facility and retail pharmacy) with sponsored research in cancer and infectious disease. In FY2025 (year ended June 30, 2025) total revenues and other support were $2,511,452 thousand, up from $2,064,034 thousand, against operating expenses of $2,428,690 thousand. It served 72K+ patients with 650+ health care providers, 460 faculty members and 6,200+ staff. Thomas J. Lynch Jr., MD is president and director.

## Business units

- **Clinical program services (patient care)** (about 63% of FY2025 revenues (patient service revenue $1,583,727 thousand)): Inpatient and outpatient cancer care, a 20-bed licensed hospital, a proton facility and retail pharmacy operations, serving 72K+ patients and 123K+ outpatient visits in FY2025, including 362 adult bone marrow transplants. Patient service revenue grew from $1,301,802 thousand in FY2024; Commercial payors brought $904,707 thousand and Medicare $596,688 thousand. Chief medical officer Tom Purcell leads the clinical side.
- **Research program services** (about 20% of FY2025 revenues (research grants and contracts $500,242 thousand)): Sponsored cancer, infectious disease and biomedical research funded by grants and contracts, about 84% of it from federal agencies. Research revenue declined from $542,770 thousand in FY2024, and awarded but not yet earned grants and contracts stood at $385,667 thousand at June 30, 2025. Programmes include TakePART-Northwest, the Vanguard Study of multi-cancer detection tests and the Cancer AI Alliance.
- **International and affiliated research entities**: Controlled entities include the Hutchinson Centre Research Institute in Uganda (infection-related cancers), the Hutchinson Centre Research Institute of South Africa (HIV/AIDS, tuberculosis, other infectious diseases and cancer) and the Seattle Vaccine Research Fund, which provides anti-retrovirals to HIV Trials Network participants.
- **Philanthropy and investments**: Contributions reached $194,395 thousand in FY2025 (FY2024 $119,308 thousand) from 42,959 donors, and investment income and realized gains were $138,019 thousand. Investments stood at $908,051 thousand and endowment net assets at $439,674 thousand.

## Strategic priorities

- **Faster patient access**: Chief medical officer Tom Purcell wants new patients on the schedule within 48 to 72 hours, by restructuring new-patient appointments and organising clinics in teams and pods supporting APPs and physicians.
- **Capacity growth in transplant and immunotherapy**: Growth over the past four years has created bottlenecks; Fred Hutch is evaluating capacity in all areas with UW School of Medicine departments and aims to make Blood and Marrow Transplant and immunotherapy more efficient and larger.
- **AI in administration, research and the clinic**: Fred Hutch coordinates the Cancer AI Alliance (CAIA), funded with more than $40 million from Amazon Web Services, Microsoft, NVIDIA, Deloitte and Slalom, pilots the Abridge ambient-listening tool for charting with UW and uses GI Genius in colonoscopies.
- **Survivorship and team-based care**: A survivorship group is being embedded within each disease type, with a new medical director of Adult Medical Survivorship, and doctors and APPs are paired on patient groups in pods supported by nurses and pharmacy.
- **Recruiting scientists and growing the Seattle campus**: Lynch says the downtown Seattle campus is solidified to enable growth, and recruiting top scientists is a daily topic with his senior leaders, with a focus on curative approaches to cancer.
- **Reaching underserved regions**: Fred Hutch wants its data and care to reach the rural parts of Washington state, Alaska and Idaho.

## Latest results

In FY2025 (year ended June 30, 2025) total revenues and other support rose to $2,511,452 thousand from $2,064,034 thousand (+21.7%, computed), driven by patient service revenue of $1,583,727 thousand. Operating expenses rose to $2,428,690 thousand from $2,102,011 thousand, with supplies and pharmaceuticals the fastest-growing line at $732,382 thousand versus $574,247 thousand. The change in net assets from operations turned positive at $82,762 thousand (FY2024: $(37,977) thousand), though the without-donor-restriction operating line was still a deficit of $(1,989) thousand. Cash and equivalents fell to $197,558 thousand from $311,887 thousand. The audited statements give no guidance.

## Investments and deals

- **Capital expenditure**: Additions to land, buildings, equipment and rental property were $255,477 thousand in FY2025, up from $120,156 thousand in FY2024; finance right-of-use assets rose to $112,038 thousand as two building finance leases were added.
- **Life-science real estate joint ventures**: Fred Hutch invested $209,405 thousand for 70% stakes in two Alexandria joint ventures (ARE-Seattle No. 55 and No. 56), formed in September 2024 to own and operate life-science commercial property in Seattle.
- **Series 2025A bonds**: On February 4, 2025 it issued $172,745 thousand of Series 2025A bonds for general corporate purposes and to defease the Series 2022E and Series 2014 bonds; long-term debt stands at $1,051,116 thousand.
- **Sloan Clinic and precision oncology**: The South Lake Union outpatient complex, serving more than 60,000 patients per year, was renamed the Sloan Clinic after a gift that expands the Stuart and Molly Sloan Precision Oncology Institute.

## Challenges and risks

- **Federal research funding exposure**: About 84% of research revenue comes from federal agencies, and research grants and contracts already fell to $500,242 thousand from $542,770 thousand; Lynch calls federal funding his biggest concern.
- **Rising supply and pharmaceutical costs**: Supplies and pharmaceuticals reached $732,382 thousand in FY2025 versus $574,247 thousand, and salaries, wages and benefits $856,251 thousand.
- **Capacity bottlenecks and change management**: Growth has put pressure on bottleneck areas, and reshuffling clinical responsibilities into pods involves what Purcell describes as a lot of change management affecting daily jobs.
- **Payments to UW Medicine**: Collaborative arrangement expense with UW Medicine rose to $78,943 thousand from $50,056 thousand, with a recorded long-term liability of $428,824 thousand.
- **Leverage and falling cash**: Long-term debt of $1,051,116 thousand carries a 1.10 times debt service coverage covenant, while cash fell to $197,558 thousand.

## What leadership says

> "We're at a time now of amazingly fast discoveries, as long as we don't stop federal funding for research. That's my biggest concern." — Thomas J. Lynch Jr., MD, President and Director, Seattle magazine interview, From Vision To Victory, August 14, 2025

> "We're growing our profile in the curative approach to cancer. And that's what the next 50 years is all about." — Thomas J. Lynch Jr., MD, President and Director, Seattle magazine interview, From Vision To Victory, August 14, 2025

> "We want our patients, especially new patients, to be able to get on the schedule easily, within 48 to 72 hours." — Tom Purcell, MD, MBA, Chief Medical Officer, Fred Hutch News Service Q&A, November 6, 2025

> "Financial headwinds are looming, and there are changes in our research funding, so there is an increased burden on our clinicians to help support our mission." — Tom Purcell, MD, MBA, Chief Medical Officer, Fred Hutch News Service Q&A, November 6, 2025


## Where a supplier can help

- **Scheduling and patient-access tooling**: Tied to the 48 to 72 hour new-patient access target: scheduling, intake and clinic-workflow tools that help restructure new-patient appointments and pod-based clinics.
- **Clinical and administrative AI**: Tied to the AI priority: Fred Hutch already pilots ambient listening for charting and coordinates CAIA, so AI for documentation, scheduling, billing and data quality fits stated plans.
- **Supply chain and pharmacy cost control**: Tied to the supplies and pharmaceuticals challenge: procurement, pharmacy and inventory services that slow the fastest-growing cost line.
- **Change management for the new care model**: Tied to the team-based care and survivorship priorities: training and change-management support for clinicians moving into pods and survivorship groups.
- **Diversified research and philanthropy funding**: Tied to the federal funding challenge: industry research partnerships and fundraising technology that reduce reliance on federal grants.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Fred Hutchinson Cancer Center Consolidated Financial Statements, June 30, 2025 and 2024 (audited, FY2025)](https://fredhutch.org/content/dam/www/about-us/accountability-impact/financial-statements/fy25-audited-financial-statement.pdf)

Annual report · 2025-10-07

- Fred Hutchinson Cancer Center (Fred Hutch) is a Washington not-for-profit, 501(c)(3) corporation, an NCI-designated comprehensive cancer research center formed in April 2022 when Fred Hutchinson Cancer Research Center combined with the Seattle Cancer Care Alliance (SCCA); it runs a clinically integrated adult oncology program with University of Washington (UW) Medicine.
- FY2025 (year ended June 30, 2025, audited by KPMG): total revenues and other support $2,511,452 thousand vs $2,064,034 thousand in FY2024 (+21.7%, computed); total operating expenses $2,428,690 thousand vs $2,102,011 thousand.
- Change in net assets from operations turned positive at $82,762 thousand (FY2024: $(37,977) thousand), but the without-donor-restriction operating line was still a small deficit of $(1,989) thousand (FY2024: $(75,594) thousand).
- Clinical care is now the economic engine: patient service revenue $1,583,727 thousand (63% of revenues, computed), up from $1,301,802 thousand; payor mix Commercial $904,707 thousand, Medicare $596,688 thousand, Medicaid $70,234 thousand.
- Research grants and contracts fell to $500,242 thousand from $542,770 thousand; about 84% of research revenue comes from federal agencies, a concentration exposed to federal funding policy.
- Supplies and pharmaceuticals is the fastest-growing cost line: $732,382 thousand vs $574,247 thousand; salaries, wages and benefits $856,251 thousand; purchased services $349,450 thousand.
- Heavy investment: capex (additions to land, buildings, equipment) $255,477 thousand vs $120,156 thousand; $209,405 thousand invested for 70% stakes in two Alexandria (ARE-Seattle No. 55 and No. 56) life-science property JVs in Seattle; cash fell to $197,558 thousand from $311,887 thousand.
- Balance sheet: total assets $3,589,579 thousand, long-term debt $1,051,116 thousand (new $172,745 thousand Series 2025A bonds issued February 2025 to defease the 2022E and 2014 bonds), a $428,824 thousand collaborative-arrangement liability to UW Medicine, net assets $1,551,541 thousand.

### [Fred Hutch 2025 Annual Report: Our First 50 Years of Lifesaving Research and Care](https://www.fredhutch.org/en/about/about-the-hutch/annual-report/2025-annual-report.html)

Report

- Fred Hutch's 2025 Annual Report marks the organisation's 50th anniversary and covers fiscal year 2025 (July 1, 2024 - June 30, 2025).
- Scale: 72K+ patients served, 123K+ outpatient visits, 362 adult bone marrow transplants; 650+ health care providers, 460 faculty members and 6,200+ staff.
- FY2025 operating revenues $2,511,452 thousand: Patient Services $1,583,727 thousand (63.0%), Contracts and Government Grants $472,078 thousand (18.8%), Gifts and Philanthropic Grants $222,559 thousand (8.9%), Investment Income $138,019 thousand (5.5%), Other Income $95,069 thousand (3.8%).
- Operating expenses $2,428,690 thousand: clinical program services 58.8%, research 29.8%, management and general 10.1%, fundraising 1.3%.
- The South Lake Union outpatient complex, which serves more than 60,000 patients per year, was renamed the Sloan Clinic after Stuart and Molly Sloan's gift to expand the Stuart and Molly Sloan Precision Oncology Institute.
- AI is a stated priority: Fred Hutch is the coordinating center of the Cancer AI Alliance (CAIA), pilots the Abridge ambient-listening tool for charting with UW, and uses GI Genius for colonoscopies.
- Research initiatives: TakePART-Northwest precision oncology program and the Vanguard Study of multi-cancer detection tests.
- Philanthropy: 42,959 donors in FY2025, with 93% of gifts under $1,000; Thomas J. Lynch Jr., MD is president and director.

### [From Vision To Victory: Dr. Thomas Lynch Jr. is forging the future of cancer care at Fred Hutch (Seattle magazine)](https://www.seattlemag.email/top-docs/from-vision-to-victory/)

Executive talk · Thomas J. Lynch Jr., MD, President and Director · 2025-08-14

- Thomas J. Lynch Jr., president and director of Fred Hutch since February 2020 and formerly chief scientific officer of Bristol Myers Squibb, led the merger with the Seattle Cancer Care Alliance.
- Fred Hutch spearheaded the Cancer AI Alliance (CAIA) with more than $40 million in funding from Amazon Web Services, Microsoft, NVIDIA, Deloitte and Slalom.
- Lynch sees AI changing medicine in three ways: administrative work (scheduling, lab results, billing, insurance), research (CAIA), and clinical medicine (notes, documentation, decision support).
- CAIA brought together four cancer centers to share data through federated learning, avoiding data-sharing agreements that take "two years of lawyers going back and forth".
- His biggest concern is federal research funding: "as long as we don't stop federal funding for research. That's my biggest concern."
- Growth plan: the downtown Seattle campus is "solidified", recruiting top scientists is a daily priority, and the "curative approach to cancer" is "what the next 50 years is all about".
- Philanthropy is essential: "You can't do this just based on federal funding." Fred Hutch wants to reach underserved rural Washington, Alaska and Idaho.

### [Delivering the best possible cancer care: Q&A with chief medical officer Tom Purcell (Fred Hutch News Service)](https://www.fredhutch.org/en/news/center-news/2025/11/delivering-the-best-possible-cancer-care-.html)

Executive talk · Tom Purcell, MD, MBA, Chief Medical Officer · 2025-11-06

- Tom Purcell, MD, MBA, chief medical officer and clinical leader of Fred Hutch, oversees an organisation-wide initiative to improve care delivery and expand capacity for more patients.
- Three focus areas: patient access, clinical care model and capacity.
- Access target: new patients on the schedule "within 48 to 72 hours", by restructuring new-patient appointments and clinic teams and pods supporting APPs and physicians.
- Survivorship: a survivorship group embedded within each disease type; Dr. Vidhya Nair hired as medical director of Adult Medical Survivorship, Theresa Wittenberg as APP Survivorship Senior Manager.
- Team-based care: doctors and APPs paired on patient groups in pods, supported by nurses and pharmacy - "a ton of change management".
- Capacity: growth since he joined four years ago has created bottlenecks; he is integrating care with UW School of Medicine departments.
- Blood and Marrow Transplant and immunotherapy are areas of worldwide expertise to be made more efficient and grown.
- He warns: "Financial headwinds are looming, and there are changes in our research funding", putting more burden on clinicians to support the mission.

## Questions about Fred Hutch

### What does Fred Hutch do?

Fred Hutch is a Seattle not-for-profit, NCI-designated comprehensive cancer center that combines cancer and infectious disease research with patient care. It runs a clinically integrated adult oncology program with UW Medicine.

### What is Fred Hutch's revenue?

In FY2025 (year ended June 30, 2025) total revenues and other support were $2,511,452 thousand, of which patient services were $1,583,727 thousand (63.0%).

### How many people work at Fred Hutch?

The 2025 Annual Report counts 650+ health care providers, 460 faculty members and 6,200+ staff.

### Who leads Fred Hutch?

Thomas J. Lynch Jr., MD has been president and director since February 2020; Tom Purcell, MD, MBA is chief medical officer.

### What is Fred Hutch's strategy?

It is expanding clinical capacity and new-patient access, growing transplant and immunotherapy, investing in AI through the Cancer AI Alliance, and focusing on curative approaches to cancer.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
